Jason Butler
Stock Analyst at JMP Securities
(2.22)
# 2,508
Out of 4,818 analysts
135
Total ratings
34.81%
Success rate
-3.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $38.00 | +105.26% | 16 | Apr 10, 2025 | |
| RAPP Rapport Therapeutics | Initiates: Market Outperform | $28 | $11.45 | +144.54% | 1 | Apr 8, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $1.62 | +270.37% | 9 | Mar 20, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $6.84 | +382.46% | 2 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Market Outperform | $17 → $18 | $7.27 | +147.59% | 2 | Mar 12, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $4 | $0.94 | +325.53% | 7 | Mar 5, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $696 → $701 | $594.65 | +17.88% | 8 | Feb 28, 2025 | |
| PRTA Prothena Corporation | Reiterates: Market Outperform | $80 | $9.61 | +732.90% | 8 | Feb 21, 2025 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $29 → $33 | $10.79 | +205.98% | 1 | Feb 21, 2025 | |
| RZLT Rezolute | Maintains: Market Outperform | $8 → $9 | $3.97 | +126.70% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $22 | $1.81 | +1,118.84% | 4 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $58.43 | +24.94% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $2.83 | +218.58% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $39 | $9.50 | +310.53% | 4 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.29 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $0.78 | +2,848.72% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $8.45 | +124.85% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $39 | $14.66 | +166.03% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $13.55 | +180.55% | 7 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $0.77 | +2,743.85% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.79 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $6.35 | +661,317.32% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $5.63 | +1,960.39% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.24 | +177.78% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.32 | - | 1 | Dec 2, 2020 |
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $38.00
Upside: +105.26%
Rapport Therapeutics
Apr 8, 2025
Initiates: Market Outperform
Price Target: $28
Current: $11.45
Upside: +144.54%
Precigen
Mar 20, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.62
Upside: +270.37%
ABIVAX Société Anonyme
Mar 18, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $6.84
Upside: +382.46%
Zevra Therapeutics
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $7.27
Upside: +147.59%
Esperion Therapeutics
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.94
Upside: +325.53%
argenx SE
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $594.65
Upside: +17.88%
Prothena Corporation
Feb 21, 2025
Reiterates: Market Outperform
Price Target: $80
Current: $9.61
Upside: +732.90%
Dynavax Technologies
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.79
Upside: +205.98%
Rezolute
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.97
Upside: +126.70%
Nov 26, 2024
Reiterates: Market Outperform
Price Target: $22
Current: $1.81
Upside: +1,118.84%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $58.43
Upside: +24.94%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.83
Upside: +218.58%
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $39
Current: $9.50
Upside: +310.53%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.29
Upside: -
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $0.78
Upside: +2,848.72%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $8.45
Upside: +124.85%
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $14.66
Upside: +166.03%
Nov 14, 2023
Maintains: Market Outperform
Price Target: $42 → $38
Current: $13.55
Upside: +180.55%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $0.77
Upside: +2,743.85%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.79
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $6.35
Upside: +661,317.32%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $5.63
Upside: +1,960.39%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.24
Upside: +177.78%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.32
Upside: -